Takeda’s Acquisition of NDI-034858 from Nimbus Therapeutics

Cleary Gottlieb represented Takeda in the transaction while Goodwin Procter advised Nimbus Therapeutics.Takeda (TSE:4502/NYSE:TAK) announced that it will acquire NDI-034858 from Nimbus Therapeutics. NDI-034858 is an…

This content is for Standard 1 Year members only.
Login Join Now
Laura Testa

Author: Laura Testa

This content is for Standard 1 Year members only.
Login Join Now